A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Summary

The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)

Timeline

Start

2024-03-21

Primary completion

2028-06-30

Completion

2029-10-26

Publications

• Siu LL, Burtness B, Harrington K, Psyrri A, Saba NF, Tahara M, Carlson G, Dhar A, Grimshaw M, Hua L, Iadevaia R, Theti D, Vlahovic G, Machiels JP. JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC. Future Oncol. 2026 Feb;22(3):313-320. doi: 10.1080/14796694.2026.2619653. Epub 2026 Jan 30.

Drugs

Indications